MTOR and nonpapillary renal cell carcinoma: Tyrosine kinase inhibitors targeting VEGF (such as sunitinib and pazopanib) and mTOR inhibitors (such as everolimus and temsiromus) are the standard-of-care therapy for ccRCC patients [6].